CA3216894A1 - An anti-tslp fab with improved stability - Google Patents
An anti-tslp fab with improved stability Download PDFInfo
- Publication number
- CA3216894A1 CA3216894A1 CA3216894A CA3216894A CA3216894A1 CA 3216894 A1 CA3216894 A1 CA 3216894A1 CA 3216894 A CA3216894 A CA 3216894A CA 3216894 A CA3216894 A CA 3216894A CA 3216894 A1 CA3216894 A1 CA 3216894A1
- Authority
- CA
- Canada
- Prior art keywords
- fab
- tslp
- cells
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169183 | 2021-04-19 | ||
| EP21169183.7 | 2021-04-19 | ||
| PCT/EP2022/060236 WO2022223514A1 (en) | 2021-04-19 | 2022-04-19 | An anti-tslp fab with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3216894A1 true CA3216894A1 (en) | 2022-10-27 |
Family
ID=75588042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3216894A Pending CA3216894A1 (en) | 2021-04-19 | 2022-04-19 | An anti-tslp fab with improved stability |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240199730A1 (https=) |
| EP (1) | EP4326767A1 (https=) |
| JP (1) | JP2024516962A (https=) |
| KR (1) | KR20230172508A (https=) |
| CN (1) | CN117222665A (https=) |
| AR (1) | AR125379A1 (https=) |
| AU (1) | AU2022263281A1 (https=) |
| BR (1) | BR112023021587A2 (https=) |
| CA (1) | CA3216894A1 (https=) |
| CL (1) | CL2023003082A1 (https=) |
| CO (1) | CO2023015286A2 (https=) |
| CR (1) | CR20230533A (https=) |
| EC (1) | ECSP23086870A (https=) |
| IL (1) | IL307651A (https=) |
| MX (1) | MX2023012266A (https=) |
| PH (1) | PH12023552762A1 (https=) |
| SA (1) | SA523451188B1 (https=) |
| TW (1) | TW202306982A (https=) |
| WO (1) | WO2022223514A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551022A1 (en) * | 2019-10-28 | 2023-03-06 | Medimmune Ltd | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202529811A (zh) | 2024-01-29 | 2025-08-01 | 瑞典商阿斯特捷利康公司 | 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法 |
| US20260034317A1 (en) | 2024-05-20 | 2026-02-05 | Medimmune Limited | Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| KR102666879B1 (ko) * | 2017-04-12 | 2024-05-23 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| EP4025602A4 (en) * | 2019-09-04 | 2023-12-13 | Biosion, Inc. | TSLP BINDING ANTIBODIES AND USES THEREOF |
| PH12022551022A1 (en) * | 2019-10-28 | 2023-03-06 | Medimmune Ltd | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof |
-
2022
- 2022-04-19 PH PH1/2023/552762A patent/PH12023552762A1/en unknown
- 2022-04-19 BR BR112023021587A patent/BR112023021587A2/pt unknown
- 2022-04-19 CN CN202280029099.0A patent/CN117222665A/zh active Pending
- 2022-04-19 WO PCT/EP2022/060236 patent/WO2022223514A1/en not_active Ceased
- 2022-04-19 IL IL307651A patent/IL307651A/en unknown
- 2022-04-19 KR KR1020237038201A patent/KR20230172508A/ko active Pending
- 2022-04-19 CR CR20230533A patent/CR20230533A/es unknown
- 2022-04-19 TW TW111114769A patent/TW202306982A/zh unknown
- 2022-04-19 JP JP2023563876A patent/JP2024516962A/ja active Pending
- 2022-04-19 EP EP22724429.0A patent/EP4326767A1/en active Pending
- 2022-04-19 US US18/287,240 patent/US20240199730A1/en active Pending
- 2022-04-19 AU AU2022263281A patent/AU2022263281A1/en active Pending
- 2022-04-19 CA CA3216894A patent/CA3216894A1/en active Pending
- 2022-04-19 AR ARP220101003A patent/AR125379A1/es unknown
- 2022-04-19 MX MX2023012266A patent/MX2023012266A/es unknown
-
2023
- 2023-10-17 CL CL2023003082A patent/CL2023003082A1/es unknown
- 2023-10-18 SA SA523451188A patent/SA523451188B1/ar unknown
- 2023-11-14 CO CONC2023/0015286A patent/CO2023015286A2/es unknown
- 2023-11-16 EC ECSENADI202386870A patent/ECSP23086870A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024516962A (ja) | 2024-04-18 |
| MX2023012266A (es) | 2023-10-24 |
| TW202306982A (zh) | 2023-02-16 |
| CL2023003082A1 (es) | 2024-04-19 |
| EP4326767A1 (en) | 2024-02-28 |
| CN117222665A (zh) | 2023-12-12 |
| CO2023015286A2 (es) | 2024-02-05 |
| BR112023021587A2 (pt) | 2023-12-19 |
| SA523451188B1 (ar) | 2025-06-22 |
| KR20230172508A (ko) | 2023-12-22 |
| AR125379A1 (es) | 2023-07-12 |
| AU2022263281A9 (en) | 2023-11-16 |
| CR20230533A (es) | 2024-04-05 |
| IL307651A (en) | 2023-12-01 |
| PH12023552762A1 (en) | 2024-04-15 |
| AU2022263281A1 (en) | 2023-11-09 |
| US20240199730A1 (en) | 2024-06-20 |
| ECSP23086870A (es) | 2023-12-29 |
| WO2022223514A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240199730A1 (en) | An anti-tslp fab with improved stability | |
| KR102330596B1 (ko) | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 | |
| CN105026428B (zh) | PD‑l抗体、其抗原结合片段及其医药用途 | |
| CN101970489B (zh) | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 | |
| US11673950B2 (en) | ILT7 binding molecules and methods of using the same | |
| CN103974975B (zh) | 抗假单胞菌Psl结合分子及其用途 | |
| CN110540590B (zh) | 一种自免疫抑制物的开发和应用 | |
| CN112654640B (zh) | 抗IL-1β的抗体、其药物组合物及其用途 | |
| CN108473568A (zh) | 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子 | |
| US20200385453A1 (en) | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | |
| WO2023036127A1 (zh) | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 | |
| KR20240017006A (ko) | 조작된 이중 결합 항체 및 이의 용도 | |
| TWI863317B (zh) | 抗cd40抗體和抗pd-l1×cd40雙特異抗體及其應用 | |
| EA052142B1 (ru) | Fab К TSLP С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ | |
| JP5476310B2 (ja) | ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物 | |
| WO2025108343A1 (zh) | 靶向il-11的抗原结合蛋白 | |
| CN121135878A (zh) | 针对ox40l和il-13的双特异性抗体及其用途 | |
| CN117616043A (zh) | 经工程化的双重结合抗体及其用途 | |
| CN115340604A (zh) | Tim-3全人源单克隆抗体及其应用 | |
| BR112018067951B1 (pt) | Anticorpo anti- transcrito 7 semelhante à imunoglobulina, composição farmacêutica e uso dos mesmos | |
| JP2012105657A (ja) | ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物 | |
| JP2015129187A (ja) | ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物 | |
| NZ721624B2 (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |